Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study May 9, 2022 | Biotech & Healthcare, Companies News, Industry Visit Resverlogix Corp. page for more research, discussion boards and to like, and share. Source: https://finance.yahoo.com/news/resverlogix-announces-type-c-meeting-111500223.html
